{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:46:07Z","timestamp":1784126767695,"version":"3.55.0"},"reference-count":153,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>B-cell lymphoma and lymphoproliferative diseases represent a heterogeneous and complex group of neoplasms that are accompanied by a broad range of immune regulatory disorder phenotypes. Clinical features of autoimmunity, hyperinflammation, immunodeficiency and infection can variously dominate, depending on the immune pathway most involved. Immunological imbalance can play a role in lymphomagenesis, also supporting the progression of the disease, while on the other hand, lymphoma acts on the immune system to weaken immunosurveillance and facilitate immunoevasion. Therefore, the modulation of immunity can have a profound effect on disease progression or resolution, which makes the immune system a critical target for new therapies. In the current therapeutic scenario enriched by chemo-free regimens, it is important to establish the effect of various drugs on the disease, as well as on the restoration of immune functions. In fact, treatment of B-cell lymphoma with passive immunotherapy that targets tumor cells or targets the tumor microenvironment, together with adoptive immunotherapy, is becoming more frequent. The aim of this review is to report relevant data on the evolution of the immune system during and after treatment with targeted therapy of B-cell lymphomas.<\/jats:p>","DOI":"10.3390\/ijms23063368","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T13:24:59Z","timestamp":1647869099000},"page":"3368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy"],"prefix":"10.3390","volume":"23","author":[{"given":"Salvatrice","family":"Mancuso","sequence":"first","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mattana","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Carlisi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Oncology, AOUP \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4390-8388","authenticated-orcid":false,"given":"Marco","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"719140","DOI":"10.3389\/fonc.2021.719140","article-title":"Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies","volume":"8","author":"Perincheri","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_3","unstructured":"National Comprehensive Cancer Network (2019). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B Cell Lymphomas, NCCN. Version 4."},{"key":"ref_4","first-page":"1","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic Lymphocytic Leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/107327481502204s02","article-title":"Chronic Lymphocytic Leukemia in the Elderly: Epidemiology and Proposed Patient-Related Approach","volume":"22","author":"Balducci","year":"2015","journal-title":"Cancer Control"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","volume":"2008","author":"Dearden","year":"2008","journal-title":"Hematology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3324\/haematol.2016.149252","article-title":"Trained immunity: Consequences for lymphoid malignancies","volume":"101","author":"Stevens","year":"2016","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0165-2478(87)90110-6","article-title":"C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance","volume":"14","author":"Miszlay","year":"1987","journal-title":"Immunol. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2014.146","article-title":"Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL","volume":"29","author":"Middleton","year":"2015","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3109\/10428194.2012.750723","article-title":"Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia","volume":"54","author":"Kontoyiannis","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Huergo-Zapico, L., Acebes-Huerta, A., Gonzalez-Rodriguez, A.P., Contesti, J., Gonzalez-Garc\u00eda, E., Payer, A.R., Villa-Alvarez, M., Fern\u00e1ndez-Guiz\u00e1n, A., L\u00f3pez-Soto, A., and Gonzalez, S. (2014). Expansion of NK cells and reduction of NKG2D expression in chronic Lymphocytic leukemia. correlation with progressive disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108326"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019 s who of T-cell differentiation: Human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/ejh.12880","article-title":"Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia","volume":"98","author":"Taghiloo","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00580-014-1961-3","article-title":"Regulatory T cells in chronic lymphocytic leukemia","volume":"24","author":"Aref","year":"2015","journal-title":"Comp. Clin. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: Pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Grywalska, E., Zaborek, M., \u0141yczba, J., Hrynkiewicz, R., B\u0119bnowska, D., Becht, R., Sosnowska-Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., and G\u00f3\u017ad\u017a, S. (2020). Chronic Lymphocytic Leukemia-Induced Humoral Immunosuppression: A Systematic Review. Cells, 9.","DOI":"10.3390\/cells9112398"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4","article-title":"Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance","volume":"61","author":"Rozman","year":"1988","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/1042819031000063408","article-title":"Vaccination against infections in chronic lymphocytic leukemia","volume":"44","author":"Sinisalo","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pasiarski, M., Rolinski, J., Grywalska, E., Stelmach-Goldys, A., Korona-Glowniak, I., Gozdz, S., Hus, I., and Malm, A. (2014). Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients\u2014Preliminary report. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114966"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1003050","article-title":"CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation","volume":"186","author":"Garaud","year":"2011","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Chatzikonstantinou","year":"2020","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/idr13040077","article-title":"Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?","volume":"13","author":"Hanssen","year":"2021","journal-title":"Infect. Dis. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: A multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2010.89","article-title":"Immune recovery after fludarabine\u2013cyclophosphamide\u2013rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy","volume":"24","author":"Ysebaert","year":"2010","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bjh.15722","article-title":"Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: A population-based analysis","volume":"184","author":"Hartley","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","article-title":"Attenuation of CD8+ T-cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Yang, Z.-Z., Grote, D.M., Ziesmer, S.C., Xiu, B., Yates, N.R., Secreto, F.J., Hodge, L.S., Witzig, T.E., Novak, A.J., and Ansell, S.M. (2013). Soluble and membrane-bound TGF-\u03b2-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059456"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2014.84","article-title":"TGF-\u03b2 upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e002662","DOI":"10.1136\/jitc-2021-002662","article-title":"Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma","volume":"9","author":"Wu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of Disease within 24 Months in Follicular Lymphoma Is Associated with Reduced Intratumoral Immune Infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"13471","DOI":"10.1038\/s41598-019-50029-y","article-title":"Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen","volume":"9","author":"Milcent","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","article-title":"Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL","volume":"117","author":"Christopoulos","year":"2011","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","article-title":"Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab","volume":"93","author":"Rabasa","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_49","first-page":"1","article-title":"An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment","volume":"2021","author":"Liang","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_50","first-page":"258","article-title":"Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?","volume":"6","author":"Roufaiel","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2018.10.003","article-title":"Curing diffuse large B-cell lymphomas in elderly patients","volume":"58","author":"Moccia","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12979-018-0130-y","article-title":"Immunosenescence and lymphomagenesis","volume":"15","author":"Mancuso","year":"2018","journal-title":"Immun. Ageing"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/bloodadvances.2021004286","article-title":"Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP","volume":"5","author":"Eyre","year":"2021","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.30739","article-title":"Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era","volume":"123","author":"Howlader","year":"2017","journal-title":"Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.19.01937","article-title":"Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma","volume":"38","author":"Shree","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1080\/10428194.2019.1569231","article-title":"Modulation of immune checkpoint molecule expression in mantle cell lymphoma","volume":"60","author":"Harrington","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3324\/haematol.2012.071340","article-title":"Immune evasion of mantle cell lymphoma: Expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells","volume":"98","author":"Wang","year":"2013","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"European Conference on Infections in Leukemia (ECIL). Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: Hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428191003699860","article-title":"High incidence of Pneumocystis jiroveciipneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone","volume":"51","author":"Kamel","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3109\/10428190903258780","article-title":"Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma","volume":"50","author":"Katsuya","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1440-1797.2009.01168.x","article-title":"Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection","volume":"14","author":"Shelton","year":"2009","journal-title":"Nephrology"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jiang, X., Mei, X., Feng, D., and Wang, X. (2015). Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122171"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral Blood CD4 + T-Lymphocyte Counts During Pneumocystis carinii Pneumonia in Immunocompromised Patients without HIV Infection","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hon.947","article-title":"Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab","volume":"29","author":"Kurokawa","year":"2011","journal-title":"Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000449251","article-title":"Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma","volume":"91","author":"Ito","year":"2016","journal-title":"Oncology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2017-0147","article-title":"Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia","volume":"10","author":"Aguinaga","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results from a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_79","first-page":"1","article-title":"Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL","volume":"6","author":"Kratzer","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1182\/blood-2018-99-118133","article-title":"Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed\/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study","volume":"132","author":"Caimi","year":"2018","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-021-03833-x","article-title":"Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: A narrative review with focus on diffuse large B-cell lymphoma","volume":"148","author":"Zinzani","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clml.2019.10.004","article-title":"Risk of Infection Associated with Ibrutinib in Patients with B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"20","author":"Ball","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Mauro, F.R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A.M., Chiarenza, A., Ciolli, S., Vitale, C., and Laurenti, L. (2021). Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Cancers, 13.","DOI":"10.3390\/cancers13133240"},{"key":"ref_89","first-page":"e7837","article-title":"Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report","volume":"12","author":"Reddy","year":"2020","journal-title":"Cureus"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bjh.17732","article-title":"Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib","volume":"195","author":"Terol","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"23","author":"Furman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_100","first-page":"E966","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Kohrt","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13046-021-02115-1","article-title":"Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively","volume":"40","author":"Moreno","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1084\/jem.20040920","article-title":"Bruton\u2019s tyrosine kinase is essential for human B cell tolerance","volume":"200","author":"Ng","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis","year":"2020","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.3324\/haematol.2015.138289","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"101","author":"Vitale","year":"2016","journal-title":"Haematologica"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"727531","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets\u2014Beyond B Lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: Updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hon.2667","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients with Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_117","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs. bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1182\/blood-2018-99-113134","article-title":"The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity","volume":"132","author":"Mathew","year":"2018","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"Hofland","year":"2019","journal-title":"Blood Adv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1124\/pr.116.012682","article-title":"Targeting Immune Checkpoints in Hematologic Malignancies","volume":"68","author":"Alatrash","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: From the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","article-title":"Infectious complications in patients treated with immune checkpoint inhibitors","volume":"141","author":"Karam","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Deshpande, R.P., Sharma, S., and Watabe, K. (2020). The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers, 12.","DOI":"10.3390\/cancers12102983"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1002\/cncr.25983","article-title":"Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2991\/chi.k.201108.001","article-title":"CART Cell Toxicities: New Insight into Mechanisms and Management","volume":"2","author":"Zahid","year":"2020","journal-title":"Clin. Hematol. Int."},{"key":"ref_136","first-page":"20499361211036773","article-title":"Infectious complications of CAR T-cell therapy: A clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_137","first-page":"749","article-title":"CAR-T cell therapy and infection: A review","volume":"19","author":"Haeusler","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(20)30376-8","article-title":"Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: Is there an excess risk for infection?","volume":"8","author":"Gudiol","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: Timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Garner, W., Samanta, P., and Haidar, G. (2021). Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions. J. Fungi, 7.","DOI":"10.3390\/jof7020156"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/sci-2021-008","article-title":"Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting","volume":"8","author":"Thakkar","year":"2021","journal-title":"Stem Cell Investig."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/leu.2016.161","article-title":"Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells","volume":"30","author":"Pizzi","year":"2016","journal-title":"Leukemia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fonc.2018.00054","article-title":"Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells","volume":"8","author":"Menter","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"594556","DOI":"10.3389\/fimmu.2020.594556","article-title":"Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia","volume":"11","author":"Griggio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.3324\/haematol.2018.196543","article-title":"Immune failure, infection and survival in chronic lymphocytic leukemia","volume":"103","author":"Crassini","year":"2018","journal-title":"Haematologica"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgo.2017.02.001","article-title":"Immunotherapy comes of age: Immune aging & checkpoint inhibitors","volume":"8","author":"Elias","year":"2017","journal-title":"J. Geriatr. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:40:08Z","timestamp":1760136008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":153,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063368"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063368","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}